New hope for hard-to-treat sarcoma: drug duo targets tumor growth
NCT ID NCT05926700
First seen Dec 17, 2025 · Last updated May 17, 2026 · Updated 23 times
Summary
This study tests whether combining two drugs—cadonilimab and anlotinib—can help people with advanced or metastatic soft tissue sarcoma whose cancer worsened after standard first-line therapy. The trial enrolls 27 adults with various sarcoma subtypes. The main goal is to see how long the cancer stays under control (progression-free survival). This is not a cure, but aims to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China
Contact
Conditions
Explore the condition pages connected to this study.